Skip to main content

Trade-Ideas LLC identified

Intersect ENT

(

XENT

) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Intersect ENT as such a stock due to the following factors:

  • XENT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $16.1 million.
  • XENT has traded 130,660 shares today.
  • XENT is up 3% today.
  • XENT was down 12% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in XENT with the Ticky from Trade-Ideas. See the FREE profile for XENT NOW at Trade-Ideas

More details on XENT:

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. XENT has a PE ratio of 8. Currently there are 7 analysts that rate Intersect ENT a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Intersect ENT has been 342,700 shares per day over the past 30 days. Intersect ENT has a market cap of $655.0 million and is part of the health care sector and health services industry. Shares are up 11% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Intersect ENT as a

sell

. Among the areas we feel are negative, one of the most important has been generally deteriorating net income.

Highlights from the ratings report include:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed against the S&P 500 and did not exceed that of the Pharmaceuticals industry. The net income has significantly decreased by 32.6% when compared to the same quarter one year ago, falling from -$4.38 million to -$5.81 million.
  • INTERSECT ENT INC has improved earnings per share by 8.0% in the most recent quarter compared to the same quarter a year ago. For the next year, the market is expecting a contraction of 18.0% in earnings (-$0.89 versus -$0.75).
  • Compared to other companies in the Pharmaceuticals industry and the overall market, INTERSECT ENT INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for INTERSECT ENT INC is currently very high, coming in at 81.96%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -38.24% is in-line with the industry average.
  • Net operating cash flow has fallen to -$2.29 million from having none in the same quarter last year. Since the company had no net operating cash flow for the prior period, we cannot calculate a percent change in order to compare its growth rate with that of its industry average.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.